According to the law firm press release, Dynavax Technologies Corporation ("Dynavax" or the Company), a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. The Company’s development programs focus on vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Company’s lead products include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) there were significant adverse events associated with Dynavax’s HEPLISAV-B product, including an imbalance in the number of cardiac events during use; (ii) consequently, a commercial product launch of HEPLISAV-B was less imminent than Dynavax had led investors to believe; and (iii) as a result, Dynavax’s public statements were materially false and misleading at all relevant times.

On January 17, 2017, the Court granted a Stipulation Consolidating Cases.

On January 31, 2017, the Court appointed Lead Plaintiff and Counsel. Lead Plaintiff filed a consolidated and amended Complaint on March 17.

On September 12, 2017, the Court issued an Order granting Defendants' Motion to Dismiss with leave to amend. On October 3, Lead Plaintiff filed a consolidated and amended Complaint. Defendants filed a Motion to Dismiss the amended Complaint on November 3. On June 4, 2018, the Court issued an Order granting Defendants' Motion to Dismiss without leave to amend. Lead Plaintiff filed a notice appealing this decision on July 3. Lead Plaintiff dismissed the appeal on November 16, 2018.